Khalid Alsallumi
Research title: The feasibility of using serious adverse event rates as a measure of trial representativeness: Using Randomised controlled trials of SGLT-2 inhibitors as an example.
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Research title: The feasibility of using serious adverse event rates as a measure of trial representativeness: Using Randomised controlled trials of SGLT-2 inhibitors as an example.
Butterly, E. et al. (2022) Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. BMJ Open, 12(10), e066491. (doi: 10.1136/bmjopen-2022-066491) (PMID:36302574) (PMCID:PMC9621152)
Butterly, E. et al. (2022) Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol. BMJ Open, 12(10), e066491. (doi: 10.1136/bmjopen-2022-066491) (PMID:36302574) (PMCID:PMC9621152)